DuChemBio듀켐바이오
176750 · KOSDAQ · ₩176750 · 듀켐바이오
Valuation model · Discounted cash flow (DCF)
We use a 5-year discounted cash flow: the value of the cash the business is expected to produce, in today's money.
Fair value per share
₩4,081
vs the current price (₩6,400)
- Enterprise value
- ₩115B
- Equity value
- ₩116B
- WACC
- 7.3%
Model estimate based on the assumptions shown. Not a price target and not a buy or sell signal. This is not financial advice.
Why the model and the price differ
The model is 36% away from today's price. A gap this size usually means the market expects something the past figures don't show yet, or the model leaves something out. What we can see:
- To match today's price of ₩6,400, the model needs an operating margin of 27.3% every year (it uses 17.7%).
- Or revenue growth +11.2 points a year higher than assumed in each of the 5 years.
Treat the model as a starting point: change the assumptions to the story you believe, and compare with the multiples check below.
Bear / Base / Bull
- Bear
- ₩2,671
- −58.3%
- Base
- ₩4,081
- −36.2%
- Bull
- ₩6,409
- +0.1%
Bear: revenue growth 3 points lower every year, EBIT margin 2 points lower, WACC 1 point higher. Bull: the opposite.
Assumptions
Sign in to change the assumptions and see the results update. Sign in
Cycle options
Margin path
Every year uses the cycle-average margin (17.7%).
Revenue growth
- 8.3%
How much sales grow that year, compared with the year before.
Default: the last 1 years' revenue growth (8.3% a year, annual reports), fading to 3% by year 5.
- 7%
How much sales grow that year, compared with the year before.
Default: the last 1 years' revenue growth (8.3% a year, annual reports), fading to 3% by year 5.
- 5.7%
How much sales grow that year, compared with the year before.
Default: the last 1 years' revenue growth (8.3% a year, annual reports), fading to 3% by year 5.
- 4.3%
How much sales grow that year, compared with the year before.
Default: the last 1 years' revenue growth (8.3% a year, annual reports), fading to 3% by year 5.
- 3%
How much sales grow that year, compared with the year before.
Default: the last 1 years' revenue growth (8.3% a year, annual reports), fading to 3% by year 5.
Business
- 17.7%
Operating profit as a share of revenue.
Default: through-the-cycle average of the last 12 months and the last 2 annual reports' operating margins.
- 27.5%
Share of operating profit paid as corporate tax.
Default: Korea's top corporate tax rate (25%) plus 10% local income tax.
- 3%
The non-cash cost of wearing out equipment, added back to cash flow (% of revenue).
Default: not in the statements, so 80% of capital spending (most spending replaces equipment that wears out).
- 3.8%
Money spent on factories, equipment, software and other long-term assets (% of revenue).
Default: average of the last 2 annual reports (cash flow statements; equipment and intangibles).
- 8.9%
Stock and unpaid customer bills, less unpaid supplier bills, as a % of revenue. Each year's extra revenue ties up this much more cash.
Default: working capital (current assets less cash and deposits, minus current liabilities other than borrowings) as a share of revenue, averaged over the last 2 years.
Discount rate
- 2%
How fast cash flows keep growing every year after year 5.
Default: about Korea's long-run inflation plus real growth.
- 4.01%
Yield on Korea's 10-year government bond: the return with almost no risk.
Default: Korea Treasury Bond 10-year yield on 2026-10-30.
- 0.6
How much the share moves when the market moves: 1 means just like the market.
Default: 105 weeks of weekly returns against KOSPI (official index); raw beta 0.07, adjusted toward 1 and kept between 0.6 and 2.0.
- 5.5%
The extra return investors want for owning shares instead of bonds.
Default: a typical premium for Korean shares.
- 5.51%
The interest rate the company would pay to borrow.
Default: the 10-year yield plus a 1.5% credit spread.
Starting point
- Revenue (TTM to H1 2026)
- ₩42B
- Net debt (borrowings and leases − cash and deposits)
- ₩1.7B
- + Stakes and investments
- ₩2.7B
- Associates, long-term financial assets and deposits (book value)
- Shares
- 28,488,720
- Share price
- ₩6,400
- Market cap
- ₩182B
TTM = trailing 12 months: the last four reported quarters added together. "TTM to H1 2026" is the 12 months up to the latest quarterly or half-year report (H1 = to the end of June). Year 1 grows from there.
Past years and projection
Grey columns are reported results from the annual reports (after-tax EBIT at the model's tax rate), so you can check the growth and margin assumptions against the past. Years 1–5 are the model.
| FY2024 | FY2025 | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 | |
|---|---|---|---|---|---|---|---|
| Revenue | ₩36B | ₩39B | ₩45B | ₩48B | ₩51B | ₩53B | ₩55B |
| Growth | — | 8.3% | 8.3% | 7.0% | 5.7% | 4.3% | 3.0% |
| EBIT | ₩5.1B | ₩7.4B | ₩8B | ₩8.5B | ₩9B | ₩9.4B | ₩9.7B |
| EBIT margin | 14.3% | 19.3% | 17.7% | 17.7% | 17.7% | 17.7% | 17.7% |
| After-tax EBIT | ₩3.7B | ₩5.4B | ₩5.8B | ₩6.2B | ₩6.5B | ₩6.8B | ₩7B |
| + Depreciation | — | — | ₩1.3B | ₩1.4B | ₩1.5B | ₩1.6B | ₩1.6B |
| − Capital spending | ₩1.9B | ₩878M | ₩1.7B | ₩1.8B | ₩1.9B | ₩2B | ₩2.1B |
| − Working capital | — | −₩2.7B | ₩307M | ₩280M | ₩244M | ₩195M | ₩142M |
| Free cash flow | — | — | ₩5.1B | ₩5.5B | ₩5.9B | ₩6.2B | ₩6.4B |
| Discount factor | — | — | 0.932 | 0.869 | 0.810 | 0.755 | 0.704 |
| Present value | — | — | ₩4.8B | ₩4.8B | ₩4.8B | ₩4.7B | ₩4.5B |
Terminal value ₩130B, worth ₩92B today: 80% of enterprise value. It assumes spending settles at 110% of depreciation once growth slows to the terminal rate.
Sensitivity
Fair value per share as two inputs change; the middle is the current case.
| WACC ↓ · Terminal growth → | 1.0% | 1.5% | 2.0% | 2.5% | 3.0% |
|---|---|---|---|---|---|
| 6.3% | ₩4,250 | ₩4,607 | ₩5,048 | ₩5,606 | ₩6,334 |
| 6.8% | ₩3,875 | ₩4,164 | ₩4,514 | ₩4,945 | ₩5,490 |
| 7.3% | ₩3,560 | ₩3,798 | ₩4,081 | ₩4,423 | ₩4,844 |
| 7.8% | ₩3,292 | ₩3,491 | ₩3,723 | ₩4,000 | ₩4,334 |
| 8.3% | ₩3,061 | ₩3,228 | ₩3,422 | ₩3,650 | ₩3,920 |
Now (TTM)
- Market cap
- ₩182B
- Enterprise value
- ₩169B
- P/E
- 26.7×
- P/B
- 3.5×
- P/S
- 4.4×
- EV/EBITDA
- —
- Dividend yield
- 0.0%
Over time (at each year end)
| 2025 | 2024 | |
|---|---|---|
| Price | ₩9,520 | ₩8,150 |
| Market cap | ₩271B | ₩232B |
| P/E | 41.9× | 29.0× |
| P/B | 5.5× | 5.4× |
| P/S | 7.0× | 6.5× |
| EV/EBITDA | — | — |
| Dividend yield | 0.0% | — |
Versus similar companies
| Company | P/E | P/B | P/S | EV/EBITDA | Dividend yield |
|---|---|---|---|---|---|
| DuChemBio | 26.7× | 3.5× | 4.4× | — | 0.0% |
| Samsung Biologics | 31.9× | 7.6× | 13.9× | — | 0.0% |
| Celltrion | 27.9× | 2.5× | 9.0× | — | 0.0% |
| Alteogen | 79.4× | 28.6× | 60.3× | — | 0.1% |
| SK biopharmaceuticals | 15.2× | 6.0× | 7.1× | — | 0.0% |
| Yuhan | 23.2× | 2.3× | 2.4× | 30.2× | 0.8% |
| HLB | — | 15.4× | 54.3× | — | 0.0% |
| Similar companies (median) | 27.9× | 6.8× | 11.4× | 30.2× | 0.0% |
Calculated from end-of-day prices and filed financial statements. Not a recommendation. This is not financial advice.
Also known as: DuChemBio / 듀켐바이오 / 176750 / KRX:176750
Source: KRX statistical information